Efficacy of a new COVID-19 treatment

Randomized clinical trial, phase 2, to evaluate the efficacy of Artesunate IV alone or combined with vitamin C IV for the treatment of COVID-19

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202006899597082

Enrollment

Registered

2020-06-10

Start date

2020-04-29

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Isotonic Saline Serum

Artesunate IV

Artesunate IV plus Vit C IV

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults aged between 18 to 70 • COVID-19 confirmed by a RT-PCR test in real time 4 days before being enrolled in the clinical trial • Patients with moderate signs of COVID-19 • Patients consenting voluntarily and freely

Exclusion criteria

Exclusion criteria: Contraindications to the drug tested • Patients who require breathing apparatus (eg invasive ventilation, invasive mechanical ventilation, oxygenation of the extra-corporeal membrane) • Patients who participated in other clinical trials related to COVID-19 • Patients who received medication directly treating COVID-19 24 hours before the start of the study.

Design outcomes

Primary

Measure	Time frame
This project will provide a better understanding of the efficacy of Artesunate IV alone or combined with Vitamin C in the form of Na-ascorbate compared to ISS in Madagascar in order to develop new strategies for the management of covid -19 adapted to the local context.	—

Secondary

Measure	Time frame
Evaluate viral load during the trial period • Determine the clinical status of patients infected with COVID-19	—

Countries

Madagascar

Contacts

Public ContactMIORAMALALA Sedera

sedera.mioramalala@gmail.com+261341057733

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026